Key statistics
On Friday, LENZ Therapeutics Inc (LENZ:NSQ) closed at 12.88, 3.21% above its 52-week low of 12.48, set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 13.12 |
|---|---|
| High | 13.19 |
| Low | 12.48 |
| Bid | 12.40 |
| Offer | 14.20 |
| Previous close | 12.97 |
| Average volume | 911.68k |
|---|---|
| Shares outstanding | 31.29m |
| Free float | 30.50m |
| P/E (TTM) | -- |
| Market cap | 403.01m USD |
| EPS (TTM) | -2.11 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
- LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
- LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
- LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
- LENZ Therapeutics to Present at Upcoming Investor Conferences
- LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
- LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
- LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
- LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
- LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
More ▼
